MATRX markets a number of products employing its patented SĀPH™ technology for controlled delivery.
SĀPH technology offers several advantages over current drug delivery products for new or approved generic medicines, including the delivery of small or large molecules (biologics, and drugs), hydrophobic or hydrophilic compounds, maintaining long-term residence at the target site, minimizing side effects due to improved localization, and providing sustained delivery options avoiding the need for repeated administration.
Peptides designed for SĀPH can also be covalently conjugated to active elements (e.g, receptor binding or activity domains), such that it also forms the basis for new drug development. Matrx is pursuing use of SĀPH-derived new drugs for several therapeutic areas including peripheral artery disease and diabetic retinopathy. A summary of therapeutic focus areas and product pipeline is provided below.
Drugs or active molecules conjugated to Matrx’s SĀPH platform are approved through FDA’s NDA approval path; drugs embedded in Matrx’s SĀPH platform for delivery are typically approved through FDA’s ANDA approval path.
- Indicates conjugated drug product for (IND) regulatory approval path
|Products||Use||Target Site||Market Entry|
|*DoxoSĀPH||solid tumor therapy||solid tumors||Q2 2022|
|TaxoSĀPH||solid tumor therapy||solid tumors||Q2 2021|
|cPTSĀPH||solid tumor therapy||solid tumors||Q2 2021|
|IgSĀPH||tumor-related immune cell targeting||solid tumors||Q2 2022|
|*V10||Peripheral Artery Disease||local – IM||Q4 2025|
|24OURS-MTZ||antibacterial||local – VE||Q3 2018|
|24OURS-MC||antifungal||local – VE||Q3 2018|
|24OURS-ABF||antibacterial + antifungal||local – VE||Q4 2018|
|24OURS-ABF+||antibacterial + antifungal + probiotic||local – VE||Q4 2018|
|24OURS-CT||non-hormonal contraceptive||local – VE||Q4 2018|
|24OURS-FR||vaginal freshener||local – VE||Q3 2018|
|24OURS-FR+||vaginal freshener + probiotic||local – VE||Q4 2018|
|24OURS-ES||vaginal atrophy||local – VE||Q4 2018|
|GelClear-BB||glaucoma – β-blocker||local – ocular||Q1 2019|
|GelClear-CAI||glaucoma – CAI||local – ocular||Q1 2019|
|GelClear-BC||glaucoma – β-blocker + CAI||local – ocular||Q1 2019|
|GelClear-MD||macular degeneration||retina – intraocular||Q4 2020|
|*PepClear-DR||diabetic retinopathy – antiangiogenic||retina – intraocular||Q1 2025|
Abbr: CAI = carbonic anhydrase inhibitor; ES = estridiol; MC= miconazole;; MTZ = metronidazole; IM = intramuscular; VE = vaginal epithelium